Rock Health's first-quarter tally, out today, counts $4.0 billion of venture money into US digital health across 110 deals, up from $3.0 billion across 122 deals a year ago. The number to look at is the concentration: twelve deals of $100 million or more took 59% of the capital, the highest share since the 2021 peak, and the average check hit $36.7 million, the largest since late 2021. The quarter's biggest deal was WHOOP's $575 million. The report's own summary is that the market is active but selective, and that when everyone has AI, the technology stops being the differentiator. For readers of this site, the chart has a simpler reading.
What concentration means for you. Fewer, larger bets on consumer platforms means fewer, larger companies with a reason to find new things for you to buy. A $100 million round is not repaid by a sleep score; it is repaid by expansion — more features, more tests, more worry per member per month. The companies that take the megadeals are the ones whose pitch most convincingly promised that growth, and the growth is you. This is not a complaint about capital. It is a description of where the pressure will come from for the next three years.
Ben’s takeI read these reports for the same reason I read a tide table. Capital this concentrated goes to platforms, and platforms monetize attention and anxiety, because those scale and a clinic visit does not. The fundamentals have no line in this chart; they never will, because there is nothing to own at the end of them. That is not a failure of the market. It is the reason the market cannot be where you learn how to live well.
Loree’s takeEvery company on this list will send some of my patients to me with a question, and the questions are getting more expensive. My job is unchanged: sort the signal from the subscription. Theirs is to make that harder. The chart tells me they just got $4 billion to try.
When a health product raises nine figures, assume the next feature is for the investors. Ask what it does for you.